What is the story about?
What's Happening?
Corcept Therapeutics is set to present late-breaking data from its Phase 3 ROSELLA trial at the European Society of Medical Oncology Congress. The trial focuses on relacorilant, a selective glucocorticoid receptor antagonist, in combination with nab-paclitaxel for treating platinum-resistant ovarian cancer. The data shows statistically significant improvements in progression-free and overall survival. Relacorilant has been designated an orphan drug by the European Commission and the FDA, with a Prescription Drug User Fee Act date set for July 2026.
Why It's Important?
Platinum-resistant ovarian cancer represents a significant unmet need in oncology, with limited treatment options and poor survival rates. Corcept's relacorilant offers a novel approach by modulating cortisol activity, potentially enhancing chemotherapy efficacy. The promising trial results could lead to a new therapeutic option for patients, improving survival and quality of life. The orphan drug designation highlights the therapy's potential impact in addressing rare and challenging cancers.
What's Next?
Corcept plans to continue its clinical development of relacorilant, with a focus on expanding its use in earlier lines of therapy and other malignancies. The upcoming presentation at ESMO will provide further insights into the trial results and potential applications. The company is also preparing for regulatory submissions and commercialization efforts, aiming to bring relacorilant to market by mid-2026.
AI Generated Content
Do you find this article useful?
